The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

BACKGROUND: Dysregulation of the canonical Wnt signaling pathway has been implicated in colorectal cancer (CRC) development as well as incipient stages of malignant transformation. In this study, we investigated the antitumor effects of AZ1366 (a novel tankyrase inhibitor) as a single agent and in c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Quackenbush, Kevin S., Bagby, Stacey, Tai, Wai Meng, Messersmith, Wells A., Schreiber, Anna, Greene, Justin, Kim, Jihye, Wang, Guoliang, Purkey, Alicia, Pitts, Todd M., Nguyen, Anna, Gao, Dexiang, Blatchford, Patrick, Capasso, Anna, Schuller, Alwin G., Eckhardt, S. Gail, Arcaroli, John J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053726/
https://ncbi.nlm.nih.gov/pubmed/27070088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8626
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares